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Mitochondrial division inhibitor-1 
is neuroprotective in the A53T-α-
synuclein rat model of Parkinson’s 
disease
Simone Bido1,2, Federico N. Soria  1,2, Rebecca Z. Fan3,4, Erwan Bezard  1,2 & Kim Tieu  3,4
Alpha-synuclein (α-syn) is involved in both familial and sporadic Parkinson’s disease (PD). One of the 
proposed pathogenic mechanisms of α-syn mutations is mitochondrial dysfunction. However, it is not 
entirely clear the impact of impaired mitochondrial dynamics induced by α-syn on neurodegeneration 
and whether targeting this pathway has therapeutic potential. In this study we evaluated whether 
inhibition of mitochondrial fission is neuroprotective against α-syn overexpression in vivo. To 
accomplish this goal, we overexpressed human A53T-α- synuclein (hA53T-α-syn) in the rat nigrostriatal 
pathway, with or without treatment using the small molecule Mitochondrial Division Inhibitor-1 
(mdivi-1), a putative inhibitor of the mitochondrial fission Dynamin-Related Protein-1 (Drp1). We show 
here that mdivi-1 reduced neurodegeneration, α-syn aggregates and normalized motor function. 
Mechanistically, mdivi-1 reduced mitochondrial fragmentation, mitochondrial dysfunction and 
oxidative stress. These in vivo results support the negative role of mutant α-syn in mitochondrial 
function and indicate that mdivi-1 has a high therapeutic potential for PD.
Parkinson’s disease (PD) is the second most common chronic neurodegenerative disorder after Alzheimer’s dis-
ease. It has been estimated that up to 10 million people worldwide are affected by PD. This number will drasti-
cally increase over time with our aging population. Disease-modifying therapies for this devastating disorder 
are urgently needed. We recently demonstrated that blocking Dynamin-Related Protein-1 (Drp1), a mitochon-
drial fission protein, rescued synaptic dysfunction and prevented cells death in the 1-methyl-4-phenyl-1,2,3,6
-tetrahydropyridine (MPTP)-treated and Pink1-knockout mouse models of nigrostriatal dysfunction1, suggesting 
the potential clinical relevance to PD. The broad applicability of this therapeutic strategy and its translational 
potential in PD were investigated in the α-synuclein (α-syn) rat model in this study.
Available abundantly in presynaptic terminals, α-syn is a small 14 kDa protein that has received significant 
attention since it was discovered twenty years ago as the first genetic mutation in PD2–5. Recent genome-wide 
association studies have identified SNCA (that encodes α-syn) as a major gene associated with sporadic PD6–8. 
Identifying pathogenic mechanisms and effective therapies for α-syn neurotoxicity is thus relevant to familial, 
sporadic PD and other synucleinopathies. Although the exact physiological function of α-syn is still incompletely 
understood, missense mutations (A53T, A30P, E46K, H50Q and G51D) or gene multiplication mutations leading 
to higher levels of wild type α-syn cause autosomal-dominant PD2–5, 9, 10. α-syn is natively unfolded in solution11, 
but it has a propensity to form aggregates under various pathological conditions12. The aggregated and insol-
uble fibrillar form of α-syn constitutes a major component of the intracellular proteinaceous inclusions called 
Lewy bodies. Many interrelated pathogenic mechanisms of α-syn mutations have been proposed13–15, including 
mitochondrial dysfunction. Relevant to the present study, α-syn has been reported in recent years to induce 
severe mitochondrial fragmentation both in vitro and in vivo, although it is still a topic of debate whether this 
defect is a result of increased fission, impaired fusion or both, or reduced connectivity between mitochondria and 
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endoplasmic reticulum16–20. However, the clinical relevance of targeting mitochondrial dynamics has not been 
determined in α-syn animal models.
Mitochondrial dynamics are controlled by fission and fusion proteins. Fusion requires the coordination of 
both the inner (IMM) and the outer (OMM) mitochondrial membranes. The OMM proteins Mitofusin 1 & 2 
(Mfn1/2) coordinate with the IMM Optic Atrophy-1 (Opa1) to join the membrane. Mitochondrial Fission Factor 
(Mff), Fission-1 (Fis1), as well as Mitochondrial Dynamics Proteins of 49 and 51 kDa (MiD49 and MiD51, respec-
tively) are anchored to the OMM where they recruit cytosolic Dynamin-related protein-1 (Drp1), which then 
oligomerizes and forms a ring-like structure around the mitochondria to constrict and split them into smaller 
ones21. Because Drp1 can bind to multiple fission proteins to sever mitochondria, directly targeting Drp1 is more 
effective to block mitochondrial fission. Furthermore, the translational potential of this target is enhanced by the 
availability of the small molecule inhibitor.
Mitochondrial division inhibitor (mdivi-1) was first identified as an inhibitor of mitochondrial divi-
sion in yeast screens of approximately 23,000 compounds22. Its protective effects through blocking mito-
chondrial fission have been reported in cultured cells23–28 and mouse models1, 26, 29–33 of a wide range of 
diseases. We recently characterized its brain and plasma kinetics and demonstrated that it was protective in the 
Pink1-knockout and MPTP-treated mouse models of PD1. We report in this study that mdivi-1 is effective against 
hA53T-α-syn-induced neurodegeneration, protein aggregation, mitochondrial abnormalities, oxidative stress 
and motor impairment in rats.
Results
Mdivi-1 prevents motor function deficits and neurodegeneration. We previously demonstrated 
that blocking mitochondrial fission, using whether rAAV-gene transfer technology or mdivi-1 to block Drp1 
function, reduced neurodegeneration and synaptic dysfunction in MPTP-treated and Pink1-null mice1. However, 
due to the inherent limitations of these models, it was not feasible to assess motor function in those animals. In 
our newly developed and characterized virally induced human A53T-α-synuclein (hA53T-α-syn) rat model, 
there is progressive motor impairment and neurodegeneration34. Combined with the significant role of α-syn in 
PD, this model is highly suitable for testing the translational potential of mdivi-1. As we previously reported34, 
four weeks after receiving stereotaxic injection of hA53T-α-syn into the substantia nigra pars compacta (SNc, 
Fig. 1a), rats exhibited progressive and severe motor impairment as compared to the control group that received 
rAAV-GFP (Fig. 1b). Twice daily intraperitoneal (i.p.) injection of mdivi-1 [20 mg/kg, a dosage regimen that we 
previously characterized1], however, completely normalized this abnormality – even up to the 8 week-end point 
of this study (Fig. 1b). At the end of this behavioral study, animals were euthanized and further processed for 
biochemical and neuropathological alterations.
To correlate the change in striatal dopamine (DA) to motor function, we used High Performance Liquid 
Chromatography (HPLC) to quantify striatal DA content in these animals (Fig. 1c–f). Consistent with the 
observed motor function, severe DA depletion was detected after 8 weeks of expressing hA53T-α-syn (Fig. 1c). 
Other metabolites of DA were not affected (Fig. 1d,e). hA53T-α-syn also accelerates the turnover rate of DA 
(Fig. 1f). Mdivi-1 prevented the reduction of DA (Fig. 1c) and its high turnover rate (Fig. 1f) induced by 
hA53T-α-syn. Of note, mdivi-1 did not affect the total levels of DA and its metabolites in the GFP control ani-
mals, suggesting that blocking Drp1 does not have a detectable detrimental effect on healthy neurons.
Next, we performed stereological cell counting for accurate measure of the population of nigral dopaminergic 
neurons in these animals. Density of striatal dopaminergic fibers was also quantified. Consistent with the alter-
ations in motor function and striatal DA content, hA53T-α-syn induced a dramatic loss of nigral dopaminergic 
neurons (Fig. 2a,b) and their striatal terminals (Fig. 2c,d). Mdivi-1 treatment conferred a significant protection in 
this nigrostriatal pathway. Together, these data strongly support the translational value of using mdivi-1 to reduce 
neurodegeneration and associated motor function deficits in PD.
Mdivi-1 reduces proteinase K-resistant and phosphorylated α-synuclein. Aggregated and 
phosphorylated α-syn are prominent features in PD. Reducing such aggregation has long been proposed as a 
therapeutic strategy for this disease. To evaluate if mdivi-1 would reduce such modified α-syn, we performed 
immunohistochemistry on coronal sections containing substantia nigra (Fig. 3). In animals with hA53T-α-syn 
transduction, significantly increased levels in phosphorylated serine 129 α-syn and proteinase K-resistant α-syn 
were detected. However, mdivi-1 significant reduced the levels of these pathogenic α-syn forms, despite the fact 
that it did not change the overall levels of hA53T-α-syn. Taken together, these results indicate that mdivi-1 is 
capable of reducing protein aggregation and toxic phosphorylated α-syn.
Mdivi-1 attenuates mitochondrial fragmentation. α-syn has been demonstrated to induce severe 
mitochondrial fragmentation in a number of cell culture studies16–20. In a recent in vivo study, mice with inducible 
expression of hA53T-α-syn in dopaminergic neurons exhibited severe mitochondrial fragmentation in a time 
dependent manner prior to axonal damage and progressive loss of these neurons19. However, to date, it is not clear 
whether mdivi-1 would prevent mitochondrial fragmentation in a hA53T-α-syn rodent model. To this end, we 
performed immunohistochemistry using Heat Shock Protein 60 (HSP60) as a mitochondrial marker and quan-
tified mitochondrial morphology. Consistent with this previous animal study19, we also observed significantly 
fewer numbers of mitochondria with tubular morphology in rats that received rAAV9- hA53T-α-syn (Fig. 4). 
Mdivi-1 treatment provided protection against such morphological alterations in mitochondria. Although there 
was a trend of less tubular and more spherical mitochondria in the GFP control group, the difference is not sta-
tistically significant. Nevertheless, the absence of elongated mitochondria as we previously observed in mice1 was 
unexpected. Based on our previous extensive dose-response study of this molecule and overexpression of pro-
teins that promote mitochondrial fusion (Mfn2), promote fission (Fis1) and blocking fission (Drp1-K38A)23, it is 
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possible that the appearance of this spherical morphology was due to enhanced fission inhibition. In our previous 
study, using rat dopaminergic neuronal cells, we observed that mdivi-1 lost the ability to promote mitochon-
drial elongation in some cells at increasing concentrations. High levels of expression of Mfn2 and Drp1-K38A 
produced similar effects23. Together, these results suggest that a gene-dose effect of promoting mitochondrial 
elongation is an inverted U-shape response. Further supporting this idea, studies from other laboratories also 
observed smaller/fragmented mitochondria in cells with overexpression of Opa135 and Mfn236. Of importance in 
the present study is that mdivi-1 prevented mitochondrial fragmentation induced by α-syn-A53T.
Mdivi-1 improves mitochondrial function in striatal synaptosomes. α-syn has been demonstrated 
in rodent models to reduce striatal presynaptic DA release19, 37–41 and impair mitochondrial respiration in the 
striatum42. Together, these observations are consistent with the critical role of mitochondria in synaptic function. 
To address whether blocking Drp1 improved mitochondrial function in the present study, we isolated synap-
tosomes from the striatum of rats with hA53T-α-syn or GFP with or without mdivi-1 treatment and measured 
mitochondrial function using XFe96 Extracellular Flux Analyzer as described43. This technology allows measure-
ment of mitochondrial respiration in relatively small quantity and thus facilitates the assessment in specific brain 
regions. As seen in Fig. 5, one week after gene delivery (an early time point that induces about 50% cell death)34, 
hA53T-α-syn significantly impaired maximal rate of mitochondrial respiration as compared to the control group, 
resulting in reduced spare respiratory capacity (Fig. 5b). These results are consistent with a previous observation 
Figure 1. Mdivi-1 preserves motor function, dopamine levels and dopamine turnover rate against hA53T-
α-syn-induced neurotoxicity. (a) Schematic illustration of the experimental design. (b) Sprague Dawley rats 
(6 weeks old) were assessed for locomotor function using stepping test. Afterwards, these animals were either 
injected with mdivi-1 (20 mg/kg, i.p) or vehicle control twice daily for the whole duration of the experiment. 
Three days after the initiation of mdivi-1 treatment, animals were stereotaxically injected with either AAV- 
hA53T-α-syn or AAV-GFPdegron control. Motor function was assessed every second week. Mdivi-1 treatment 
prevented motor deficits induced by hA53T-α-syn. HPLC was used to quantify total striatal dopamine (DA) 
content (c) as well as DA metabolites, (d) 3,4-Dihydroxyphenylacetic acid (DOPAC) and (e) Homovanillic acid 
(HVA). hA53T-α-syn induced significant DA depletion and increased DA turnover as evidenced by the ratio 
of DOPAC/DA (f). Mdivi-1 reduced this high turnover rate of DA (e) and restored the normal striatal level of 
DA (c). Mdivi-1 had no effect when injected in control animals (GFP). (b) Values are means ± SEM for 7–8 rats 
and were analyzed by 2-way ANOVA. (time: F4,135 = 224.5 p < 0.001; treatment: F3,135 = 32.81 p < 0.001; time 
x treatment: F12,135 = 5.651 p < 0.001) followed by Tukey multiple comparison test (p < 0.001 versus hA53T-
α-syn vehicle injected animals). Data from neurochemistry (c–f) were analysed using two-way ANOVA (AAV 
injection: F1,26 = 10.57 p = 0.003; treatment: F1,26 = 7.916 p = 0.009; AAV injection x treatment: F1,26 = 1.984 
p = 0.1708) followed by Tukey multiple comparison test (*p < 0.05; **p < 0.01; ***p < 0.001 compared to A53T 
vehicle).
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using human induced pluripotent stem cell (hiPSC) with hA53T-α-syn44. Spare respiratory capacity is the ability 
of mitochondria to provide substrate supply and electron transport to response to an increase in energy demand. 
A reduction in spare respiratory capacity leads to energy crisis when energy demand exceeds the supply ability of 
mitochondria. Indeed, spare respiratory capacity has been considered as a major factor that defines the survival of 
the neuron43. Mdivi-1 significantly improved spare respiratory capacity in animals with hA53T-α-syn.
Mdivi-1 prevents oxidative stress. It is well-established that mitochondrial fragmentation and dys-
function generate oxidative stress. We asked whether oxidative stress also occurred in our animal model and if 
so, whether mdivi-1 would reduce it. To address this question, we performed immunohistochemistry to detect 
4-hydroxy-2-nonenal (4-HNE), a major product generated from lipid peroxidation as a result of free radical 
attack. Eight weeks after AAV-hA53T-α-syn injection in rats, a high level of 4-HNE in nigral dopaminergic 
neurons was evident as compared to those transduced with AAV-GFP. Consistent with the effect of mdivi-1 on 
preserving mitochondrial morphology and function, mdivi-1 blocked the production of 4-HNE in the group of 
animals that received hA53T-α-syn (Fig. 6).
Discussion
As we discussed in our recent reviews13, 14, misfolded α-syn (whether as a result of mutations, exposure to envi-
ronmental toxins or infection) induces cellular dysfunction and neurodegeneration through several distinct 
but non-mutually exclusive mechanisms. For example, because of its strong propensity to bind to membranes, 
Figure 2. Mdivi-1 attenuates nigrostriatal degeneration induced by hA53T-α-syn. (a) Representative pictures 
of TH immuno-staining in SNc, scale bar 200 μm. (b) Stereological quantification in SNc showing a decrease 
in the total number of TH positive neurons in animals expressing hA53T-α-syn. The decrease was prevented 
in A53T rats injected with mdivi-1. (c) Representative pictures of TH staining in striatum. Scale bar 1 mm. 
(d) Optical density of TH positive fibers was reduced in rat expressing hA53T-α-syn compared to GFP and 
preserved in mdivi-1-treated A53T animals. (b,d) Values are means ± SEM of 7–8 rats analysed using two-
way ANOVA (b), AAV injection: F1,26 = 43.79 p < 0.001; treatment: F1,26 = 3.919 p = 0.0584; AAV injection x 
treatment: F1,26 = 11.12 p = 0.0026; (d) AAV injection: F1,27 = 7.83 p = 0.009; treatment: F1,27 = 7.664 p = 0.0101; 
AAV injection x treatment: F1,27 = 1.504 p = 0.23) followed by Tukey multiple comparison test (*p < 0.05; 
**p < 0.01; ***p < 0.001 to A53T vehicle, ^p < 0.05 to A53T mdivi-1).
www.nature.com/scientificreports/
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Figure 3. Mdivi-1-mediated neuroprotection is accompanied by a decrease in phospho- and PK-resistant 
α-syn. (a) Representative pictures of α-syn immuno-staining in SN of AAV-hA53T-α-syn and AAV-GFP 
transduced rats. From left to right: total (endogenous rat α-syn+ human A53T-α-syn), human A53T, 
phosphorylated and PK-resistant A53T α-syn. Scale bar 50 μm. (b) When quantified, the expression of total 
α-syn is higher in rats injected with hA53T-α-syn and increases further after mdivi-1 treatment, suggesting 
mdivi-1 preserved more dopaminergic structures. (c) As expected, higher levels of human α-syn were 
detectable in animals with hA53T-α-syn transduction. Mdivi-1 did not affect the total levels of this protein. 
(d) The level of phosphorylated α-syn was increased in A53T animals and, mdivi-1 treatment attenuated this 
upregulation. (e) Following PK treatment, a strong hA53T-α-syn immunoreactivity persisted in A53T animals. 
This signal was significantly reduced in A53T rats treated with mdivi-1. The quantification was carried out 
using an automated threshold in one slice per animal. Values are means ± SEM for 7–8 animals analysed by 
two-way ANOVA (b) AAV injection: F1,27 = 16.68 p < 0.001; treatment: F1,27 = 3.611 p = 0.0681; AAV injection 
x treatment: F1,27 = 3.476 p = 0.0732; (d) AAV injection: F1,27 = 22.69 p < 0.001; treatment: F1,27 = 3.176 
p = 0.0859; AAV injection x treatment: F1,27 = 4.066 p = 0.0538; e, AAV injection: F1,27 = 31.45 p < 0.001; 
treatment: F1,27 = 5.217 p = 0.0305; AAV injection x treatment: F1,27 = 5.635 p = 0.025) followed by Tukey 
multiple comparison test (*p < 0.05; ***p < 0.001 to A53T vehicle, ^^p < 0.01 to A53T mdivi-1)
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6SCIeNtIfIC RePoRtS | 7: 7495 | DOI:10.1038/s41598-017-07181-0
α-syn localizes to organelles such as lysosomes, endoplasmic reticulum and mitochondria. Indeed, it has been 
well-reported that α-syn impairs the function of these organelles. Combined with its ability to inhibit the 
ubiquitin-proteosomal and autophagic pathways, protein aggregation is a common observation in α-syn asso-
ciated toxicity. In addition to these cell-autonomous mechanisms, α-syn also activates microglia and induces 
Figure 4. Mdivi-1 reduces mitochondrial fragmentation in dopaminergic neurons induced by hA53T-α-
syn. Coronal midbrain sections containing SN of rats after 8 weeks of receiving AAV-hA53T-α-syn or AAV-
GFPdegron with or without mdivi-1 treatment were immunostained with a mitochondrial marker HSP60 
(red) and TH (not shown). Scale bar 5 μm. Different mitochondrial morphologies were categorized into three 
populations according to their shapes: tubular, intermediate and spheric (representative pictures bottom 
panel a, scale bar 1 μm). (b,c,d) Abundance in different mitochondria populations. Panel B shows a decrease 
in the relative number of tubular mitochondria in neurons of rats expressing hA53T-α-syn. This phenotype 
was reversed following mdivi-1 treatment. Fluorescent images were captured as single layer. Values are 
means ± SEM for 50–80 TH+ neurons per group. Statistical analysis was performed using two-way ANOVA 
(b) AAV injection: F1,246 = 8.144 p = 0.0047; treatment: F1,246 = 1.069 p = 0.3023; AAV injection x treatment: 
F1,246 = 17.47 p < 0.001;(c) AAV injection: F1,246 = 8.008 p = 0.005; treatment: F1,246 = 1.569 p = 0.2115; AAV 
injection x treatment: F1,246 = 0.3536 p = 0.5526) followed by Tukey multiple comparison test (*p < 0.05; 
**p < 0.01; ***p < 0.01 to A53T vehicle).
Figure 5. Mdivi-1 attenuates mitochondrial dysfunction in isolated synaptosomes. Mitochondrial function 
in striatal synaptosomes was assessed by measuring oxygen consumption rate (OCR) using the XFe96 
Extracellular Flux Analyzer. (a) Sequential injections of oligomycin (to inhibit oxygen consumption mediated 
by ATP synthase), FCCP (an uncoupler to induce maximal OCR), Rotenone/Antimycin (to inhibit complex 
I and III, respectively). Values obtained from (a) were then used to calculate Spare Respiratory Capacity as a 
% = (Maximal Respiration)/(Basal Respiration) × 100 (b). Data represent means ± SEM of 5 five animals per 
group (except for the GFP+ mdivi-1 group, n = 3), Statistical analysis was performed using two-way ANOVA 
(AAV injection: F1,14 = 26.12 p < 0.001; treatment: F1,14 = 4.07 p = 0.063; AAV injection x treatment: F1,14 = 1.19 
p = 0.294) followed by Tukey multiple comparison test (*p < 0.05 to A53T vehicle).
www.nature.com/scientificreports/
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Figure 6. Mdivi-1 decreases ROS-mediated lipid oxidation in A53T animals. (a) Representative pictures of 
4-HNE staining (red) measured in TH positive neurons (green). Scale bar 30 μm. (b) Dopaminergic cells of 
animals expressing hA53T-α-syn display an increase of lipid oxidation that turned back to basal levels in the 
presence of mdivi-1 treatment. Quantification was carried out measuring the levels of grey of 4-HNE staining 
in 16-bit images. Fluorescent images are captured as single layer. Values are means ± SEM for 7–8 rats (6 cells 
are analysed for each rat) and were analysed by two-way ANOVA (AAV injection: F1,27 = 5.196 p = 0.0308; 
treatment: F1,27 = 4.014 p = 0.0552; AAV injection x treatment: F1,27 = 16.91 p < 0.001) followed by Tukey 
multiple comparison test (*p < 0.05; **p < 0.01; ***p < 0.001 to A53T vehicle).
www.nature.com/scientificreports/
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neuroinflammation, resulting in a non-cell autonomous-mediated toxicity. With such multiple pathogenic mech-
anisms, various therapeutic strategies have been developed over years to combat α-syn associated pathologies13. 
In the present study, we addressed the critical question of whether protecting mitochondrial integrity and func-
tion would be sufficient to attenuate α-syn-induced neurotoxicity in vivo.
Using our well-characterized virally induced hA53T-α-syn rat model34, we demonstrated that the putative 
Drp1 inhibitor mdivi-1 is highly effective in reducing dopaminergic neurodegeneration and motor dysfunction. 
At biochemical and cellular levels, mdivi-1 increased striatal DA content, reduced protein aggregation and oxi-
dative stress, as well as reduced mitochondrial fragmentation and improved mitochondrial function. Altogether 
these results support the negative impact of α-syn on mitochondria and that blocking mitochondrial fission is 
protective against α-syn neurotoxicity. The results of our study are consistent with the role of α-syn in causing 
mitochondrial dysfunction in other in vivo studies. For example, Chesselet et al. demonstrated that mice with 
global overexpression of human wild type α-syn in the brain using the Thy1 promoter exhibited age dependent 
accumulation of α-syn in mitochondria in the nigrostriatal dopaminergic pathway, impaired electron transport 
chain function and enhanced oxidative stress42. Recently, Greenamyre’s laboratory reported that specific forms 
of post-translationally modified α-syn bind with high affinity to the mitochondrial receptor TOM20, resulting 
in mitochondrial dysfunction and production of reactive oxygen species45. From the Zhuang’s group, inducible 
hA53T-α-syn mice exhibited severe mitochondrial fragmentation that preceded dopaminergic neurodegenera-
tion and other pathologies19. Using double immunogold-transmission electron microscopy, presence of the trans-
genic α-syn protein in mitochondria was clearly identified in these mutant mice. We also observed mitochondrial 
fragmentation in our present study using rAAV-hA53T-α-syn rat model. More importantly, for the first time, 
we demonstrated that blocking in vivo application of mdivi-1 is highly protective against hA53T-α-syn-induced 
neurodegeneration and other associated pathologies. The observation of mdivi-1 reducing accumulation of pro-
teinase K-resistant and phosphorylated Ser129-α-syn is potentially significant. Additional studies are required 
to elucidate the mechanism of these effects. However, we hypothesize that the mechanism is mediated, at least 
in part, by improving mitochondrial function and reducing oxidative stress, because the autophagic and ubiq-
uitin proteasomal pathways are energy dependent and sensitive to oxidative stress. A recent study has similarly 
reported that mdivi-1 reduced the accumulation of amyloid-beta plaque in double transgenic mice APP/PS1 
model of Alzheimer’s disease33.
Manipulating mitochondrial fission/fusion has been considered as a potential novel mitochondrial therapy 
in recent years46–48. Within this context, blocking Drp1 is the most highly pursued strategy, partly because of the 
availability of a putative inhibitor (mdivi-1). Other investigators have demonstrated that blocking Drp1 function 
is protective in PD cell culture models of PINK123, LRRK249, 50 or VPS3526 mutations, and of rotenone51, MPP+ 52, 53  
or 6-hydroxydopamine54 neurotoxins, as well as in Pink1−/− and MPTP-treated mice1. The protective role of 
blocking Drp1 in α-syn cell culture models is not quite definitive. Although some studies demonstrated that 
blocking Drp1 protected mitochondria from α-syn, others show that mitochondrial fragmentation induced by 
α-syn is Drp1 independent16–18, 20, 55. As often, conflicting data in cell culture models could be difficult to interpret 
due to different cell systems and experimental conditions. We believe that evaluations of the translational values 
of blocking Drp1 should extend beyond in vitro mitochondrial morphology and function, and that it should be 
conducted in mammalian animal models with brain pathologies and motor impairment as seen in PD. In this 
regard, the present study has provided some insights.
One potential concern of blocking mitochondrial fission as a therapeutic strategy is the possibility of develop-
ing side effects, because a balance of fission and fusion is necessary for the maintenance of neuronal function. This 
is an issue that will need to be considered if and when this treatment is to be conducted in clinical trials. Based on 
current literature, however, naive wild type mice are viable and no abnormal phenotypes are detectable up to ten 
weeks after the treatments of Drp1 inhibition, whether this is achieved by systemic injection of mdivi-11, 28–31, 33, 56–58  
or a peptide (P110-TAT)59 or by localized gene therapy1. Cytotoxicity of this molecule was not detectable at 
cellular, biochemical and functional levels, as shown in these publications and in the present study. Peripheral 
injections of mdivi-1 do not affect blood pressure, oxygen saturation, pH and blood cell counts56. Germline dele-
tion of Drp1, however, induces embryonic lethality and degeneration of Purkinje neurons in mice60–62. Mice with 
conditional knockout of Drp163 or Mfn264 also indicate that nigrostriatal dopaminergic neurons are vulnerable 
to complete deletion of fission and fusion proteins. Interesting mice with heterozygous deletion of Drp1 have 
normal lifespan, phenotype, mitochondrial and synaptic structures65. Crossing these Drp1+/− mice with either the 
transgenic AβPP mice (Tg2576) or with Tau P301L transgenic mice reduced toxic soluble proteins and improved 
mitochondrial function in these animal models of Alzheimer’s disease66, 67. Together these studies indicate that 
there is a gene-dose effect of loss of Drp1 function on its associated negative impact on neuronal function and 
viability. Furthermore, partial Drp1 loss of function appears to be safe and sufficient to confer neuroprotection.
Mdivi-1 has been demonstrated independently by many laboratories to have striking protective effects in a 
wide-range of disease models both in vitro and in vivo. The interest in the translational potential of this molecule 
is therefore understandably high. However, recent studies have raised the question of the specific mechanism of 
action of mdivi-1. Initially discovered by Nunnari and colleagues, mdivi-1 was shown to be specific and potent 
inhibitor of GTPase activity of yeast Dnm1, a homolog of mammalian Drp122. Subsequently, this small mole-
cule was also demonstrated to block Drp1 GTPase activity in human recombinant Drp168 and in mammalian 
neuronal cells28. GTPase activity of Drp1 is required for Drp1 oligomerization. Largely based on evidence from 
studies such as these ones, mdivi-1 has been considered in general as a Drp1 inhibitor. However, studies from the 
laboratory of Reddy showed that mdvi-1 also increased the levels of mitochondrial fusion proteins (Mfn1/2 and 
Opa1) and reduced the levels of Drp1 in neuronal cells27, 28. It has also been demonstrated in vivo to reduce the 
levels of phosphorylated Drp1-S616 induced by kainic acid in the mouse hippocampus58. Taken together, these 
studies indicate that mdivi-1 is capable of blocking mitochondrial fission and promoting mitochondrial fusion 
at both enzymatic and protein expression levels. It is worth noting that also using human recombinant Drp1, a 
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recent study reported that mdivi-1 is a weak and non-specific inhibitor of Drp1 GTPase69. Instead, this molecule 
was reported to be a reversible inhibitor of complex I and ROS production generated via reverse electron transfer 
mechanism. More studies are clearly required to reconcile this discrepancy and explain why blocking complex I 
would confer protection observed in other studies. Rather than using recombinant Drp1, perhaps an intact mam-
malian cell system should be used to determine whether mdivi-1 would block Drp1 function either directly or 
indirectly. Taken together, it is clear so far that mdivi-1 confers striking protective effects across multiple disease 
models, but most likely not exclusively through Drp-1 inhibition.
In summary, the present study reports that mdivi-1 is highly effective in reducing neurodegeneration, motor 
dysfunction and accumulation of toxic α-syn, mitochondrial damage and oxidative stress in a rat α-syn model 
of PD. This study further highlights the translational potential of mdivi-1. In addition to the present study, this 
small molecule has been demonstrated to be beneficial in other rodent models of PD1, Huntington’s disease28, 
Alzheimer’s disease33, epilepsy58, renal30, cardiac29, brain ischemic damage31, 70, neuropathic pain57 and diabetes32. 
With such a striking neuroprotective property in a wide range of diseases, mdivi-1 and perhaps strategies of 
blocking Drp1 function hold great promise to novel therapies.
Methods
Antibodies. Primary. Mouse anti-TH (1:10000, 1:2000 for SNc and striatum respectively, clone LNC1, 
Millipore); mouse anti-α-synuclein (1:1000, BD Transduction Laboratories); mouse anti-human-α-synuclein 
(1:1000, clone LB509, Invitrogen); rabbit anti-α-synuclein-P-S129 (1:1000, Abcam ab59264); goat anti-HSP60 
(1:20, Santa Cruz Biotechnology); Rabbit anti-4-HNE (1:200, Alpha Diagnostic).
Secondary. All the secondary antibodies used for the immunofluorescience staining are anti-IgG conjugated 
with Alexa FluorTM 488 or 568. For HRP immunohistochemistry labeling, the HRP Dako Envision PolymerTM 
conjugated with the appropriate secondary antibody was used.
Animals and experimental design. All experiments were performed in accordance with the European 
Union directive of September 22, 2010 (2010/63/EU) after approval by Institutional Animal Care and Use 
Committee of Bordeaux (CE50) under the license number 5012066-A, and in accordance with the provisions 
laid down by the UK Home Office under the Project Licence No. PPL 30/3088. Animals had free access to water 
and food. Veterinary care includes a full program for prevention of disease, daily observation and surveillance 
for animal health, appropriate methods of disease control, diagnosis, and treatment, appropriate methods of han-
dling, restraint, anesthesia, analgesia and euthanasia as well as monitoring of surgical programs and post-surgical 
care. One week before surgery, Sprague Dawley rats (32 animals, 6 weeks old), purchased from Charles River, 
were tested for stepping test and sorted in order to generate 4 groups with no differences in the mean motor 
performance (p > 0.95). The 4 groups were then submitted to different treatments: 1) AAV-GFPdegron plus 
vehicle (GFP + veh), 2) AAV-GFPdegron plus mdivi-1 (GFP + mdivi-1), 3) AAV- hA53T-α-syn plus vehicle 
(A53T + veh) and 4) AAV- hA53T-α-syn plus mdivi-1 (A53T + mdivi-1).
Mdivi-1 treatment. As previously described1, 3-(2,4-Dichloro-5-methoxyphenyl)-2-sulfanyl-
4(3H)-quinazolinone (mdivi-1, Sequoia Research Products, UK) was dissolved in DMSO as a stock solution, 
which was then diluted with sterile 0.9% saline solution (1% DMSO final concentration), sonicated for 30 seconds 
and then promptly injected. Three days before stereotaxic injection of AAV- hA53T-α-syn or AAV-GFPdegron, 
animals were pre-treated with either mdivi-1 (20 mg/kg) or vehicle. This dosage was selected based on our previ-
ous study1, in which we characterized the in vivo pharmacokinetics and dose-response of mdivi-1. We found that 
with this dosage regimen, mdivi-1 conferred the most neuroprotective effects without detectable side-effects. The 
intraperitoneal (i.p) injections were performed twice a day (9 a.m.–18 p.m.) for eight weeks. During this period, 
every two weeks, motor performance was monitored with the stepping test. At the end of the treatment period 
animals were euthanized and brain collected for histological and neurochemical analysis. Brains were collected 
fresh and divided in three parts: bilateral mesencephalon and unilateral striatum was post fixed for 5 days in PFA 
4% and then sectioned for histological studies, while another striatum was collected fresh, flash frozen and store 
at −80 °C for neurochemical analysis.
Viral vector production. AAV9-GFPdegron and AAV9-hA53T-α-syn were produced by triple transfection 
into HEK-293T/17 cell line (ATCC, Teddington, UK) in polyethylenimine solution. After seventy-two hours cell 
were re-suspended with Tris lysis buffer (NaCl 150 mM, Tris-HCl 50 mM pH 8.5) and lysed using the freeze-thaw 
cycle procedure (−80 to +37 °C). The supernatant underwent to iodixanol gradient step purification (by centrif-
ugation), and the fraction enriched in viral vector stocked at −80 °C. These procedure were well established and 
well described in our previous publications34, 71.
Surgery procedure. Rats were bilaterally injected with AAV-GFPdegron or AAV- hA53T-α-syn (titer nor-
malized to 6.9 × 1013 gcp/ml) as previously described34. Briefly, under isoflurane anesthesia, animals were ster-
otaxically injected with 2 μL of virus into the substantia nigra pars compacta (SNc) according to the following 
coordinates: AP = −4.9/−5.4, L = −2.2/−2, DV = −7.8 from bregma.
Motor performance assessment. The stepping test was used to assess the forelimb akinesia as we recently 
described34. Rats were held and dragged sideways on a smooth surface at a constant speed for 0.9 m of distance 
and the number of adjusting steps counted. The performance was evaluated once every two weeks, three sessions 
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over two consecutive days. The scores over the three sessions were averaged and the left and right backhand steps 
were pooled together.
HPLC analysis. Fresh striatum collected after euthanasia was sonicated in HClO4 0.1 M and the homoge-
nate centrifuged at 4 °C for 30 min at 13000 rpm. 20 uL of supernatant was used for the HPLC analysis as pre-
viously described72. Monoamines were measured by coulometric detector (Coulochem II, ESA) coupled to a 
dual-electrode analytic cell (model 50110) with the potential of electrodes set at +350 and −270 mV. The samples 
were injected with a mobile phase containing NaH2PO4 70 mM, methanol 7%, sodium octyl sulfate 100 mg/L, tri-
ethylamine 100 μL/L, EDTA 0.1 mM, into an HPLC Equisil column (C18, 150 × 4.5 mm, 5 μm)72. Retention times 
for noradrenaline, DOPAC, DA, HVA and serotonin were ~250, 420, 660, 1100, 1970 sec, respectively.
Immunostaining. Tyrosine Hydroxylase. Free floating 50 μm-thick slices were rinsed in PBS and treated 
for one hour with a blocking solution containing BSA 2% and Triton × 100 0.3% in PBS. After being blocked, 
the tissue was incubated with the TH primary antibody diluted with a solution containing BSA 1%, Triton × 100 
0.3% over night at room temperature. The slices were then incubated with the secondary antibody and finally 
revealed with peroxidase EnVisionTM system (DAKO). For the SNc slices the counter coloration with cresyl violet 
was performed. The slices were mounted in gelatin-coated slides and the coverslip sealed with EukittTM mounting 
medium.
Stereological counting. The unbiased stereological sampling method was used to quantify dopaminergic 
neurons in SNc as described in many occasions34 The cell counting was performed using Leica DM600 motorized 
microscope equipped with Mercator Pro Software (Explora Nova, La Rochelle, France). After SNc boundaries 
delimitation, TH positive (TH+) cells in SNc are on-line counted at 40X magnification over five 50 μm-thick 
sections for each brain, collected every 300 μm, encompassing the whole SNc. The optical fractionator stereolog-
ical probe was then used to estimate the total number of TH+ neurons for the entire SNc volume. Considering 
the bilateral nature of our model, the data presented in this paper are the sum of neurons counted for both SNc.
Striatal TH quantification. Images were taken with Nanozoomer 2.0 HT (Hamamatsu, Japan) at 20X mag-
nification and analyzed with Image J (NIH, USA). The striatum boundaries were traced and optical density meas-
ured in terms of grey levels for 8-bit images as previously described34.
α-synuclein immunostaining and quantification. For α-syn immunolabeling we applied the same 
protocol as described above for the TH staining as previously73. The slices treated with proteinase K (PK) were 
incubated for 10 minutes in a solution with 1 μg/mL of PK prior to any step and the tissue processed for the 
immunostaining. SNc pictures were captured with NanoZoomer using 20X objective and analyzed with Image J 
software. The quantification was carried out by measuring the percentage of the SNc area occupied by the stained 
surface using an automated threshold for all the images.
Mitochondrial network staining in vivo. HSP60 immunostaining was used to characterize the mito-
chondrial phenotype in dopaminergic neurons of SNc. Free-floating coronal SNc sections of 50 µm thickness 
were rinsed in PBS, incubated for 10 min with H2O2 3% and 10% methanol, then for 20 min with Triton × 100 2%. 
BSA 3% for 1 hour was used to saturate the unspecific binding site before the overnight incubation with primary 
antibody (diluted in a solution containing BSA 1% and Triton × 100 at room temperature. Following incubation, 
sections were rinsed three times for 10 min in PBS and incubated for 1 hour with the secondary antibody. The 
same protocol was used to co-stain the TH and phosphorylated α-syn. The triple staining was needed to limit 
the quantification to dopaminergic neurons (TH positive) expressing hα-syn (indicated by the accumulation of 
phospho-syn). Single layer pictures of rat SNc were taken with confocal microscope DM6000 TCS SP5 (Leica, 
Germany) using 63 X (1.4 NA) magnification.
Mitochondrial network quantification in vivo. Every single neuron picture was analyzed through an 
Image J macro purposely designed for the quantification of the relative area, shape descriptors and number of 
mitochondrial particles occupying the cytoplasmic surface of the neuron. Moreover, the circularity index pro-
vided by the macro, allowed us to sort the entire mitochondria population fragments into three different groups 
based on their shape: 0.8 to 1 spheric; 0.5 to 0.79 intermediate; 0 to 0.49 tubular.
4-hydroxynonenal staining and quantification. TH and 4-HNE were co-stained following the same 
protocol used for the mitochondrial labeling in vivo. Single layer pictures were captured using confocal imaging 
at 40X magnification. We used a fixed laser power and AOTF levels for all the images. 16-bit pictures were then 
analyzed with Image J software measuring the level of grays of 4-HNE staining only in TH positive neurons.
Synaptosomes isolation. Synaptosomes were isolated from Sprague Dawley adult rats based on a previous 
publication43 but with some modifications. Briefly, striata were quickly removed, rinsed with ice-cold sucrose 
buffer (320 mM sucrose, 1 mM EDTA, 0.25 mM dithiothreitol, pH 7.4) and then homogenized (10–12 strokes) in 
dounce glass homogenizer containing 1–1.5 mL sucrose buffer. The homogenates were then gently layered onto 
a discontinuous Percoll gradient (2.5 ml of 3%, 10% and 23% in sucrose buffer) in 10 mL centrifuge tubes, and 
centrifuged at 32,500 g for 10 min at 4 °C in a JA-25.50 fixed angle rotor in a Beckman Avanti J-26 X centrifuge. 
The band between 10% and 23% from striatum were collected for synaptosomes, pelleted and resuspended into 
ionic buffer (20 mM HEPES, 10 mM D-glucose, 1.2 mM Na2HPO4, 1 mM MgCl2, 5 mM), protein concentrations 
were measured using nano drop 2000.
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Mitochondrial function in striatal synaptosomes. Primary based on the method developed by 
David Nicoll’s laboratory43, striatal synaptosomes (2ug/well) were plated into an XF96 cell culture microplate 
(Seahorse Bioscience Inc.) which was previously sequentially pre-coated with 0.0033% (v/v) polyethyleneimine 
(Sigma-Aldrich) and Geltrex (Invitrogen). The plate was centrifuged at 3,400 g for 1 h at 4 °C in a Henttich Rotanta 
460 R centrifuge to facilitate attachment. The ionic buffer was then replaced with 175 µL assay buffer (3.5 mM KCl, 
120 mM NaCl, 1.3 mM CaCl2, 0.4 mM KH2PO4,1.2 mM Na2SO4, 15 mM D-glucose, 10 mM pyruvate, 0.4% (w/v) 
fatty acid-free bovine serum albumin, and 10 mM TES (N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic 
acid), pH 7.4). The plate was incubated in a non-CO2 incubator at 37 °C for 10–15 min, then loaded into the 
XFe96 Extracellular Flux Analyzer (Seahorse Biosciences Inc.). Mitochondrial function in these synaptosomes, 
as indicated by oxygen consumption rate (OCR), was monitored in real-time throughout the assay. Different 
parameters of mitochondrial respiration were obtained with sequential injections of 2.5 μg/ml oligomycin, 4 μM 
FCCP and 2 μM Rotenone/Antimycin. Oxygen consumption rate data points represent the mean rates of each 
measurement cycle, which consisted of 30 s mixing time, 30 s waiting time, followed by 3 min of data acquisition. 
Basal respiration was measured before first injection (3 cycles), and 3 data points were obtained following each 
injection (12 data points in total).
Statistics. All values are expressed as mean ± SEM. Differences between means were analysed using a 
two-way analysis of variance (ANOVA) followed by Tukey multiple comparison post-hoc test using GraphPad 
Prism v5.01. The null hypothesis was rejected when P-value was <0.05.
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